Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships
Q4 2024 Management View CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, ...
Sanofi India share price rises up to 6% post Q4 results, Dividend announcements
Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...
A Boon For Investors! Pharma Giant Recommends Massive Dividend of Rs 117; A Solid Move For Shareholder Value?
With a market valuation of Rs 11,574.76 Cr, Sanofi Indias shares ended Fridays trading session on the BSE 0.58% higher at Rs ...
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Disney Sees Sell-Out for Oscars Ads — And Not Just on TV
DIsney says it has sold out all commercial inventory for Sunday's Oscars, and notes packages include TV, streaming, social ...
1 Biotech Stock to Buy in 2025, and 1 to Avoid
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
FiercePharma22h
If GSK thrives in '25, CEO Emma Walmsley's pay could more than double to $27M
For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...